These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25955280)

  • 1. A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus.
    Bhattacharya R; Zhou S; Wei W; Ajmera M; Sambamoorthi U
    J Am Geriatr Soc; 2015 May; 63(5):893-901. PubMed ID: 25955280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.
    Levin P; Zhou S; Durden E; Farr AM; Gill J; Wei W
    Clin Ther; 2016 Jan; 38(1):110-21. PubMed ID: 26681210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
    Dalal MR; Kazemi M; Ye F; Xie L
    Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study.
    Curtis B; Lage MJ
    J Med Econ; 2014 Jan; 17(1):21-31. PubMed ID: 24195723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of hypoglycemia with basal insulin in type 2 diabetes.
    Fonseca V; Chou E; Chung HW; Gerrits C
    Am J Manag Care; 2017 Feb; 23(2):114-122. PubMed ID: 28245655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries.
    Hazel-Fernandez L; Li Y; Nero D; Moretz C; Slabaugh L; Meah Y; Baltz J; Patel NC; Bouchard JR
    Am J Manag Care; 2015 Jan; 21(1):e62-70. PubMed ID: 25880269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.
    Luo J; Khan NF; Manetti T; Rose J; Kaloghlian A; Gadhe B; Jain SH; Gagne JJ; Kesselheim AS
    JAMA; 2019 Jan; 321(4):374-384. PubMed ID: 30694321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States.
    Ganz ML; Wintfeld NS; Li Q; Lee YC; Gatt E; Huang JC
    Curr Med Res Opin; 2014 Oct; 30(10):1991-2000. PubMed ID: 24945720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.